FDA Places Magenta’s ADC Conditioning Program On Hold
Insights - Magenta announced that the FDA has placed a clinical hold on their IND filed in June 2021 for conditioning agent MGTA-117. As a result, MGTA will need … Continue Reading
PremiumAuthor Archives: D Mero
Eloxx To Present CF Data in Early Q4 2021
Insights - Yesterday, Eloxx (ELOX) was down 17% to $1.60 after the company provided an enrolment update for ELX-02 Phase 2 in cystic fibrosis. The company expects to present … Continue Reading
Premium
Genentech Discontinues Affimed’s BCMA Candidate
Insights - Affimed had the Q1 business update call this morning. The call was not well received after the company did not shed much light on AFM24 progress and … Continue Reading
Premium
Jounce R&D Day 2021 Focuses on LILRB Family
Insights - Last week, Jounce hosted their R&D day to update investors on their pipeline and future prospects (watch webinar here). Overall, we thought the company provided good … Continue Reading
PremiumEloxx Risk-Reward Compelling Ahead of Cystic Fibrosis Data
Research - Eloxx (ELOX) is developing a cystic fibrosis treatment for the 12% of patients that Vertex’s therapies cannot treat. The mechanism of action in the ribosome … Continue Reading
PremiumJounce Hands Over CCR8 Clinical Development To Gilead
Insights - Earlier this week Jounce (JNCE) received a $25M milestone payment from Gilead (GILD) for advancing their anti-CCR8 antibody through IND clearance. Gilead will now develop this program, … Continue Reading
Premium
US Phase 3 Study Validates Novavax Vaccine. All Eyes on Regulatory & Manufacturing
Insights - Novavax (NVAX) reported Phase 3 from their US/Mexico trial and the data confirmed their vaccine as best in class. Novavax provided 90% overall protection and 100% protection … Continue Reading
Premium